Back to Journals » Infection and Drug Resistance » Volume 14

Managing Fungal Infections in Cystic Fibrosis Patients: Challenges in Clinical Practice

Authors Magee LC, Louis M, Khan V, Micalo L, Chaudary N

Received 26 December 2020

Accepted for publication 25 February 2021

Published 22 March 2021 Volume 2021:14 Pages 1141—1153

DOI https://doi.org/10.2147/IDR.S267219

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Héctor M. Mora-Montes


Lauren C Magee,1 Mariam Louis,2 Vaneeza Khan,3 Lavender Micalo,3 Nauman Chaudary3

1Department of Pharmacy, Virginia Commonwealth University Health System, Richmond, VA, USA; 2Department of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Jacksonville, FL, USA; 3Division of Pulmonary Disease and Critical Care Medicine, Department of Medicine, Virginia Commonwealth University, Richmond, VA, USA

Correspondence: Lauren C Magee; Nauman Chaudary
VCU Adult Cystic Fibrosis Center, Division of Pulmonary Disease and Critical Care Medicine, 1200 East Broad Street, Box 980050, Richmond, VA, 23298, USA
Tel +1 804 628-5046; +1 804 828-1579
Fax +1 804 828-2578
Email [email protected]; [email protected]

Abstract: Cystic Fibrosis (CF) is an autosomal recessive disease characterized by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Impairment of the CFTR protein in the respiratory tract results in the formation of thick mucus, development of inflammation, destruction of bronchial tissue, and development of bacterial or fungal infections over time. CF patients are commonly colonized and/or infected with fungal organisms, Candida albicans or Aspergillus fumigatus, with prevalence rates ranging from 5% to 78% in the literature. Risk factors for acquiring fungal organisms include older age, coinfection with Pseudomonas aeruginosa, prolonged use of oral and inhaled antibiotics, and lower forced expiratory volume (FEV1). There are limited data available to differentiate between contamination, colonization, and active infection. Furthermore, the pathogenicity of colonization is variable in the literature as some studies report a decline in lung function associated with fungal colonization whereas others showed no difference. Limited data are available for the eradication of fungal colonization and the treatment of active invasive aspergillosis in adult CF patients. In this review article, we discuss the challenges in clinical practice and current literature available for laboratory findings, clinical diagnosis, and treatment options for fungal infections in adult CF patients.

Keywords: cystic fibrosis, fungal infection, colonization, Candida, Aspergillus, ABPA, Aspergillus bronchitis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]